Cathie Wood’s $1.9M Biotech Bet: PRME, TWST, TEM Surge as AI Stock Gets Axed

Cathie Wood just placed a massive $1.9 million wager on biotech—while dramatically cutting exposure to artificial intelligence. Her latest moves signal a seismic shift in strategy that's sending shockwaves through growth portfolios.

Biotech Bonanza

ARK Investment Management loaded up on precision medicine plays PRME, TWST, and TEM—tripling down on genomic revolution themes while Wall Street remains obsessed with AI hype cycles. The biotech sector's been bleeding for months, but Wood sees blood in the water as a buying opportunity.

AI Exit Strategy

Meanwhile, she's trimming positions in artificial intelligence stocks—a contrarian move that's raising eyebrows among tech investors. While everyone else chases ChatGPT knockoffs, Wood's betting the real disruption happens inside our cells, not our chatbots.

Wood's track record remains divisive—her fans see visionary genius, while skeptics note her funds still haven't recovered from 2022's crypto carnage. But one thing's clear: when Cathie Wood moves $1.9 million, the market pays attention—even if it's just to place opposite bets.

Elevate Your Investing Strategy:

• Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Wood Boosts Stake in PRME and TWST Stocks

Cathie Wood’s ARK Invest was an active buyer of biotech names on Tuesday. The flagship ARK Genomic Revolution ETF (ARKG) purchased about 157,000 shares of Prime Medicine, a gene-editing company, valued at roughly $620,000.

In addition, Wood also added to TWST, a synthetic biology company that has been a frequent target in recent ARK trades. ARK bought $1.1 million worth of TWST through the ARK Innovation ETF (ARKK) and another $137,400 through ARKG, for a combined total of about $1.24 million.

In all, ARK invested nearly $1.86 million in biotech stocks on September 9, reflecting Wood’s continued conviction in the sector. Notably, PRME stock has gained 41% year-to-date, while TWST stock has fallen 46%.

Wood Trims Stakes in Tempus

On the sell side, ARK scaled back holdings in Tempus AI, a health-tech company known for its precision medicine platform. The funds sold a total of 25,936 shares across the ARKK and the ARKG ETFs, amounting to about $2.08 million.

Tempus has been one of ARK’s newer additions, but the partial trim suggests Wood is reducing exposure to select tech names while reallocating capital to other high-conviction areas.

Notably, TEM stock has surged 140% year-to-date, highlighting the strong run that may have prompted profit-taking.

Let’s take a brief look at how all these stocks perform on TipRanks’ Stock Comparison Tool: